Recent advances in imaging techniques of renal masses

Aggarwal, Ankita; Das, Chandan Jyoti; Sharma, Sanjay

doi:10.4329/wjr.v14.i6.137

Cited by 2 publications

(6 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It calculates various parameters like diffusivity (D), pseudo diffusion coefficient (D*) and perfusion index (F). A significant variation is noted in diffusion kurtosis parameters between various RCC subtypes and grades [28].…”

Section: Phase(g) and Nephrographic Phase (H) Of Similar Lesion (*) L...mentioning

confidence: 96%

“…Higher grade RCC shows higher perfusion values. In anti cholinergic drug therapy administered for metastatic RCC; changes in vascularity are achieved before the changes in the size of tumor and thus early response assessment can be done [28].…”

Section: Magnitude Spectrum Of Malignant Renal Masses (Upper Row) And...mentioning

confidence: 99%

“…Deoxyhemoglobin has a para magnetic effects and causes rapid photon dephasing. Decreased T2 relaxation time is achieved due to higher amount of deoxyhemoglobin [28]. BOLD MRI has established role in brain imaging.…”

Section: Boldmentioning

confidence: 99%

“…The changes in Larmor frequency within the magnetic field is due to differing chemical composition, which is called "chemical shift". As of now the established role of Proton spectroscopy is in imaging of central nervous system, breast and prostatic regions [28]. However Kim et al studied five patients with biopsy proven RCC and found the difference of lipid and choline as per the tumor grade (Figure 11) [31].…”

Section: Proton Spectroscopymentioning

confidence: 99%

“…Due to increased amount of mitochondria in the renal oncocytoma lesions, role of 99m Tc-Sestamibi can be rationalized for differentiating various renal masses. 99m Tc-Sestamibi SPECT/CT has sensitivity and specificity [28].…”

Section: Single Photon Emission Computed Tomography (Spect)mentioning

confidence: 99%

See 4 more Smart Citations

Current Imaging Techniques in Renal Cell Carcinoma

Patel¹

2023

Renal Cell Carcinoma - Recent Advances, New Perspectives and Applications

View full text Add to dashboard Cite

Renal cancers are one of the 10 most commonly seen cancers in both sexes. The incidence of renal cancers is high in Western developed countries and lower in Eastern and developing countries. The overall incidence of malignancy has been increasing in recent times. Ultrasound (USG) is very commonly used imaging technique; however recent advances like contrast enhanced ultrasound helps to differentiate various cystic renal masses. Availability of newer imaging techniques such as Computed tomography scan (CT scan) and Magnetic resonance imaging (MRI) and their various applications may play a role in better and early diagnosis of such lesions. Due to its highly metastatic nature, accurate staging is more important to facilitate proper treatment. Fluoro-deoxyglucose positron emission tomography (FDG PET) is widely applied in detection, staging/restaging and surveillance of such lesions. In this chapter, we will try to cover the recent advances in various modalities for detection of renal cancers, particularly renal cell carcinoma (RCC).

show abstract

Section: Phase(g) and Nephrographic Phase (H) Of Similar Lesion (*) L...mentioning

confidence: 96%

Section: Magnitude Spectrum Of Malignant Renal Masses (Upper Row) And...mentioning

confidence: 99%

Section: Boldmentioning

confidence: 99%

Section: Proton Spectroscopymentioning

confidence: 99%

Section: Single Photon Emission Computed Tomography (Spect)mentioning

confidence: 99%

See 3 more Smart Citations

Current Imaging Techniques in Renal Cell Carcinoma

Patel¹

2023

Renal Cell Carcinoma - Recent Advances, New Perspectives and Applications

View full text Add to dashboard Cite

show abstract

SEOM SOGUG clinical guideline for treatment of kidney cancer (2022)

Méndez-Vidal,

Lázaro Quintela,

Lainez-Milagro

et al. 2023

Clin Transl Oncol

View full text Add to dashboard Cite

Renal cancer is the seventh most common cancer in men and the tenth in women. The aim of this article is to review the diagnosis, treatment, and follow-up of renal carcinoma accompanied by recommendations with new evidence and treatment algorithms. A new pathologic classification of RCC by the World Health Organization (WHO) was published in 2022 and this classification would be considered a “bridge” to a future molecular classification. For patients with localized disease, surgery is the treatment of choice with nephron-sparing surgery recommended when feasible. Adjuvant treatment with pembrolizumab is an option for intermediate-or high-risk cases, as well as patients after complete resection of metastatic disease. More data are needed in the future, including positive overall survival data. Clinical prognostic classification, preferably IMDC, should be used for treatment decision making in mRCC. Cytoreductive nephrectomy should not be deemed mandatory in individuals with intermediate-poor IMDC/MSKCC risk who require systemic therapy. Metastasectomy can be contemplated in selected subjects with a limited number of metastases or long metachronous disease-free interval. For the population of patients with metastatic ccRCC as a whole, the combination of pembrolizumab–axitinib, nivolumab–cabozantinib, or pembrolizumab–lenvatinib can be considered as the first option based on the benefit obtained in OS versus sunitinib. In cases that have an intermediate IMDC and poor prognosis, the combination of ipilimumab and nivolumab has demonstrated superior OS compared to sunitinib. As for individuals with advanced RCC previously treated with one or two antiangiogenic tyrosine-kinase inhibitors, nivolumab and cabozantinib are the options of choice. When there is progression following initial immunotherapy-based treatment, we recommend treatment with an antiangiogenic tyrosine-kinase inhibitor. While no clear sequence can be advocated, medical oncologists and patients should be aware of the recent advances and new strategies that improve survival and quality of life in the setting of metastatic RC.

show abstract

Recent advances in imaging techniques of renal masses

Cited by 2 publications

References 74 publications

Current Imaging Techniques in Renal Cell Carcinoma

Current Imaging Techniques in Renal Cell Carcinoma

SEOM SOGUG clinical guideline for treatment of kidney cancer (2022)

Contact Info

Product

Resources

About